Rivelsa 91 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients on Rivelsa 91 Day (levonorgestrel/ethinyl estradiol, extended-cycle, quadriphasic) increasingly report difficulty filling their prescriptions at retail pharmacies in 2026. This guide is intended for prescribers, OB/GYNs, family medicine providers, NPs, and PAs who manage patients on this medication and need actionable clinical guidance for managing availability gaps.

Current Supply Status: What Providers Need to Know

As of 2026, Rivelsa 91 Day (Teva Pharmaceuticals, NDC 0093-6031) is not on the FDA Drug Shortage database. The drug class — extended-cycle levonorgestrel/ethinyl estradiol combination OCs — is commercially available through multiple manufacturers. However, retail pharmacy stock of Rivelsa specifically is inconsistent due to:

Lower per-pharmacy dispensing frequency (3-month supply means ~4 fills/year vs 12 for monthly pills)

PBM formulary preferences that may direct pharmacies to stock a competing 91-day generic

Automated replenishment systems that deprioritize low-frequency specialty packs

Over 15 competing extended-cycle generic brands creating fragmented inventory across pharmacy networks

Clinical Pharmacology Reminder: Why Rivelsa's Formulation Matters

Rivelsa 91 Day is a quadriphasic extended-cycle COC — the generic of Quartette (Teva). Its unique feature is a step-up ethinyl estradiol dose across the 84 active tablets: 42 tablets at 0.02 mg EE, followed by 21 tablets at 0.025 mg EE, followed by 21 tablets at 0.03 mg EE, with levonorgestrel constant at 0.15 mg throughout. The final 7 tablets contain 0.01 mg EE only (no progestin). This graduated estrogen approach was designed to minimize unscheduled bleeding and spotting compared to monophasic 91-day formulations — a clinically relevant distinction for patients switching from other extended-cycle options.

Therapeutic Substitution Options: Clinical Considerations

If Rivelsa 91 Day is unavailable and the patient cannot wait, consider the following in order of clinical similarity:

Quartette (brand): Pharmacologically identical; higher cost without insurance coverage. Use only if insurance will cover or patient can pay.

Monophasic 91-day COCs (Ashlyna, Setlakin, Simpesse, Introvale): Same duration and hormones, but constant EE dose (0.03 mg throughout active phase). May result in increased unscheduled bleeding vs. Rivelsa. Appropriate for most patients; counsel on potential for spotting increase.

Jolessa or Quasense: Monophasic 91-day COCs with inert (no EE) placebo week, meaning scheduled bleeds may be slightly heavier or shorter. Similar pharmacologic profile to Ashlyna class.

Standard 28-day LNG/EE COC (Vienva, Altavera, Kurvelo, etc.): Appropriate bridge if patient is running out immediately and cannot wait. Will restore monthly cycles. Good for temporary use.

Special Populations and Off-Label Uses: Substitution Cautions

Patients who were prescribed Rivelsa for off-label indications—such as endometriosis-associated pain suppression, menstrual migraine management, PCOS cycle regulation, or dysmenorrhea—may not achieve equivalent results from a monophasic substitute. Consider these factors before automatically substituting, and involve the patient in the decision.

Prescribing Tips to Reduce Future Availability Issues

Clinicians can help their patients avoid stock-related disruptions with these prescribing strategies:

Advise patients to begin their refill search 3 weeks before the current pack ends, not when it runs out

Consider e-prescribing to a mail-order pharmacy for reliable ongoing dispensing

When issuing paper or e-prescriptions, consider adding 'Dispense as Written' if the quadriphasic formulation is clinically essential — this prevents pharmacy substitution to a monophasic generic

Provide patients with medfinder.com as a tool to locate Rivelsa in stock quickly without multiple phone calls

Patient Counseling Points for Availability Issues

When counseling patients who have difficulty filling Rivelsa 91 Day, reinforce the following:

Do not skip doses without guidance — even 1-2 missed active tablets can reduce efficacy; backup contraception should be used

Do not take pills from a different pack out of sequence — the quadriphasic design means phase order matters

Emergency contraception (Plan B/levonorgestrel) remains available OTC if there is a concern about unprotected exposure during a medication gap

The yellow (7 low-dose EE only) tablets should not be skipped — they are active medication, not placebos

medfinder for Providers

medfinder is a service that calls pharmacies on patients' behalf to check which ones can fill their Rivelsa prescription. Directing patients to medfinder.com/providers can reduce the phone burden on your clinical team. See also: How to help your patients find Rivelsa 91 Day in stock.